Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
The Conversation logo

Since humans haven’t previously been exposed to the novel coronavirus (SARS-CoV-2), our bodies aren’t well equipped to deal with being infected by it. A vaccine would allow the body to safely develop an immune response to COVID-19 that could prevent or control infection.

But it takes time to develop safe and effective vaccines – usually five to ten years on average. Despite promising reports about potential coronavirus vaccines being developed worldwide, it could still take an estimated 12-18 months to develop one.

It’s becoming quicker to develop new vaccines than it was in the past as we can build on research from vaccines used for other diseases. During outbreaks, more resources and funding may also become available, which can speed up the process. Products might also be considered for use even before being formally granted licences to control the disease in severely affected areas during emergencies.

The development of a potential novel coronavirus vaccine is being partly led by experts who were already developing vaccines for other coronaviruses. This type of virus was identified as a possible cause of the next big pandemic as the other coronaviruses SARS and MERS have been responsible for two global outbreaks in the last 20 years. Research on vaccines for these coronaviruses was already undergoing clinical trials.

Read the full article on The Conversation website, written by Andrew Pollard (Oxford Vaccine Group, Department of Paediatrics), Samantha Vanderslott (Oxford Martin School) and Tonia Thomas (Oxford Vaccine Group, Department of Paediatrics).

Oxford is a subscribing member of The ConversationFind out how you can write for The Conversation.

 

 

Similar stories

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.

Parental mental health worsens under new national COVID-19 restrictions

Coronavirus COVID-19 General Research

Parental stress, depression and anxiety have again increased since new national restrictions have been introduced, according to the latest report from the Oxford University-led COVID-19 Supporting Parents, Adolescents, and Children in Epidemics (Co-SPACE) study, based on data from over 6000 UK parents.

£100 million donation from Ineos to create new institute to fight antimicrobial resistance

Awards and Appointments General Innovation

A new state of the art institute for antimicrobial research is to open at Oxford University thanks to a £100 million donation from Ineos.